Picture Health shared a post by OncoDaily Lung, adding:
“For decades, anti-angiogenic therapies have been administered without a reliable way to predict which patients will truly benefit. With QVT Score, we can now pinpoint the patient population that benefits most: those with complex tumor blood vessels at baseline, or higher QVT Scores.
Follow along as Rhea Chitalia, our Director of Scientific Partnerships, walks through our latest findings at ASCO 2026.”
Quoting OncoDaily Lung‘s post:
“Poster presentation by Rhea Chitalia, PhD at American Society of Clinical Oncology (ASCO).”